The Utility of Droplet Molecular Diagnostics

Clinical Validation of an FDA-cleared BCR-ABL Assay for Minimal Residual Disease Monitoring

Tuesday, August 6, 2 – 2:40 p.m.
Exhibit Hall, Theater 3
Supported by Bio-Rad Laboratories


Join us for a detailed introduction and overview of droplet digital PCR and its utility in clinical diagnostics. This presentation will focus on the recently FDA-cleared QXDx ddPCR system and the QXDx BCR-ABL % IS Kit intended to measure BCR-ABL1 in t(9;22)-positive chronic myelogenous leukemia (CML) patients during treatment with tyrosine kinase inhibitors. Additional applications and future developments for molecular oncology will also be discussed.


After attending this session, participants will be able to:

  • Describe the clinical utility of BCR-ABL monitoring for minimal residual disease in CML.
  • Realize the necessity of highly precise and accurate measurement of BCR-ABL transcripts in ongoing clinical research and trials.
  • Understand how droplet digital PCR can be utilized in the molecular diagnostic lab for a variety of applications including oncology, newborn screening, and infectious disease.


Jerald Radich, MD
Medical Oncologist, Clinical Research Division
Fred Hutchinson Cancer Research Center
Seattle, WA